Alpha Stem Cell Clinics Trials

The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials.

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha Clinic	Alpha Clinic Contact	Trial Sponsor	Disease Indication	Clinical Trial Name	Status of Enrollment	Learn More
UCI	Julia Kimberly Fong juliakf@hs.uci.edu	Cartesian Therapeutics	MYASTHENIA GRAVIS (MG)	Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)	Recruiting	Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
City of Hope	Lucy Ghoda 626-218-3605 lghoda@coh.org	City of Hope	Neurodegenerative Disorder	Acquisition of Skin Biopsy Samples from Healthy Volunteers and Patients Diagnosed with X-Linked Adrenoleukodystrophy (ALD), Canavan Disease (CD) and other Inherited Leukodystrophies	Recruiting
UCSD		Aivita	Ovarian and Fallopian Tube Carcinoma	Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas	Active, not recruiting	Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcino
UCI	Breana Chew 949-824-8116 chewbc@hs.uci.edu	Brain Neurotherapy Bio	Parkinson's	Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson’s Disease	Active, not recruiting
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Cabaletta	Pemphigus Vulgaris	Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects with Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris	Recruiting	Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in S
UCSF	Marisa Gin 415-476-3816 Marissa.Gin@ucsf.edu	Poseida Therapeutics, Inc.	Prostate cancer	A Phase 1 Dose Escalation and Expanded Cohort Study of P‑PSMA‑101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)	No longer active	NCT04249947
UCSD		Calibr	Relapsed/Refractory B-cell Lymphomas	CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies	No longer active	CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
UCSD		Calibr	Relapsed/Refractory B-cell Lymphomas	Long term follow-up study for patients administered CLBR001 , a CAR-T cell	No longer active	Long term follow-up study for patients administered CLBR001 , a CAR-T cell
UCLA	Kit L Shaw, PhD (310) 267-0584 kshaw@mednet.ucla.edu	Orchard Therapeutics	Severe Combined Immunodeficiency (SCID)	Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency	Active, not recruiting
UCLA	Kit L Shaw, PhD (310) 267-0584 kshaw@mednet.ucla.edu	UCLA	Severe Combined Immunodeficiency (SCID)	Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)	Active, not recruiting
UCSF	Kenny Truong, RN 415-502-2080 kenny.truong@ucsf.edu	Jasper Therapeutics	Severe Combined Immunodeficiency syndrome	A Phase 1 study to evaluate the safety and tolerability of tandemly-purified allogeneic CD34+CD90+ HSC administered following conditioning with JSP 191 to achieve engraftment and immune reconstitution in patients with SCID	Recruiting
UCSF	Carol Fraser-Brown 415-476-2188 carol.fraser-browne@ucsf.edu	Stanford University	Severe Combined Innunodeficiency (SCID)	AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients	Recruiting
UCSF	Cyrus Bascon 510-428-3885 ext 6953 Cyrus.bascon@ucsf.edu	CIRM & NHLBI	Severe sickle cell disease	Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease	Active, not recruiting
UCLA	Fabrizia Urbinati, PhD (310) 794-1884 furbinati@ucla.edu	UCLA	Sickle Cell Disease	Stem Cell Gene Therapy for Sickle Cell Disease	Recruiting
City of Hope	Teresa Kim 626-218-0263 teresakim@coh.org	City of Hope	Sickle Cell Disease	A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant	Recruiting
UCSF	Cyrus Bascon 510-428-3885 ext 5396 CBascon@mail.cho.org	bluebird bio	Sickle Cell Disease	A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease	No longer active	NCT02140554
City of Hope	Joseph Rosenthal, MD 626-256-4673 ext 88442 jrosenthal@coh.org	City of Hope	Sickle Cell Disease	Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO)	Recruiting
UCSF and UC Davis	Julie DeCaris 510-428-3885. ext.2739 Julie.decaris@ucsf.edu Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Bioverativ Therapeutics, Inc	Sickle Cell Disease	A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease	No longer active
UCSF	Cyrus Bascon 510-428-3885 ext 6953 Cyrus.bascon@ucsf.edu	Editas Medicine Inc.	Sickle Cell Disease	A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell D	Recruiting	NCT04853576
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Fate Therapeutics	Solid tumors	FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors	No longer active	FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors
UC Davis & UCSD & UCI & UCSF & City of Hope	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Pact Pharma & CIRM	Solid tumors	A Phase 1a/1b, Open Label First In Human Study Of The Safety, Tolerability And Feasibility Of Gene Edited Autologous NeoTCR T Cells (NeoTCR-P1) Administered As A Single Agent Or In Combination With Anti PD-1 To Patients With Locally Advanced Or Metastatic	No longer active	A Phase 1a/1b, Open Label First In Human Study Of The Safety, Tolerability And Feasibility Of Gene Edited Autologous NeoTCR T Ce
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	UC Davis/CIRM	Spina bifida	Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele	Recruiting	Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Neuralstem	Spinal Cord Injury	Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI	Recruiting
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Asterias Biotherapeutics	Spinal Cord Injury	Dose Escalation Study of AST-OPC1 in Spinal Cord Injury	No longer active
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	SanBio	Stroke	Study of Modified Stem Cells in Patients With Chronic Motor Deficit From Ischemic Stroke	No longer active
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	ReNeuron Limited	Stroke	A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects with Disability Following an Ischemic Stroke (PISCES III)	No longer active
UCSF	Rodney Rogers Rodney.Rogers@ucsf.edu	Talaris	Transplanted Organ Rejection	A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1)	No longer active	NCT03995901
UC Davis & UCSD	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Viacyte	Type 1 diabetes	An Open-Label, First-in-Human, Study Evaluating the Safety, Tolerability, and Efficacy of VC-02 Combination Product in Subjects with Type 1 Diabetes Mellitus and Hypoglycemia Unawareness	No longer active	An Open-Label, First-in-Human, Study Evaluating the Safety, Tolerability, and Efficacy of VC-02 Combination Product in Subjects
UCLA	Caroline Kuo, MD 310-794-1940 ckuo@mednet.ucla.edu	UCLA	X-linked Chronic Granulomatous Disease	Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease	Active, not recruiting

« Previous 1 2 3

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials. If you or a family member is interested in participating in a clinical trial, please visit clinicaltrials.gov to find a trial near you.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News